Gamida Cell Ltd. (GMDA)
After hours:
| Previous close | 2.6400 |
| Open | 2.7200 |
| Bid | 0.0000 x 3000 |
| Ask | 0.0000 x 1800 |
| Day's range | 2.7000 - 3.6588 |
| 52-week range | 1.4800 - 5.8400 |
| Volume | |
| Avg. volume | 475,927 |
| Market cap | 203.348M |
| Beta (5Y monthly) | 1.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
BOSTON, August 10, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces dosing of the first patient in a company-sponsored Phase 1/2 study evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas (NCT05296525).
- Business Wire
Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast
BOSTON, August 08, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast on Monday, August 15, 2022, at 8:00 a.m. ET to review its second quarter 2022 financial results and provide an update on the company.
- Business Wire
Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review
BOSTON, August 01, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. Omidubicel is a first-in-class, ad
